CA3013942C - Compositions and methods for the treatment of sinus disease and disorders - Google Patents

Compositions and methods for the treatment of sinus disease and disorders Download PDF

Info

Publication number
CA3013942C
CA3013942C CA3013942A CA3013942A CA3013942C CA 3013942 C CA3013942 C CA 3013942C CA 3013942 A CA3013942 A CA 3013942A CA 3013942 A CA3013942 A CA 3013942A CA 3013942 C CA3013942 C CA 3013942C
Authority
CA
Canada
Prior art keywords
carrageenan
flo
kappa
crs
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3013942A
Other languages
English (en)
French (fr)
Other versions
CA3013942A1 (en
Inventor
Sam BARBALATT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENT TECHNOLOGIES Pty Ltd
Original Assignee
ENT TECHNOLOGIES Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900553A external-priority patent/AU2016900553A0/en
Application filed by ENT TECHNOLOGIES Pty Ltd filed Critical ENT TECHNOLOGIES Pty Ltd
Publication of CA3013942A1 publication Critical patent/CA3013942A1/en
Application granted granted Critical
Publication of CA3013942C publication Critical patent/CA3013942C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3013942A 2016-02-17 2017-02-17 Compositions and methods for the treatment of sinus disease and disorders Active CA3013942C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016900553A AU2016900553A0 (en) 2016-02-17 Compositions and Methods for the Treatment of Sinus Diseases and Disorders
AU2016900553 2016-02-17
PCT/AU2017/050144 WO2017139854A1 (en) 2016-02-17 2017-02-17 Compositions and methods for the treatment of sinus disease and disorders

Publications (2)

Publication Number Publication Date
CA3013942A1 CA3013942A1 (en) 2017-08-24
CA3013942C true CA3013942C (en) 2024-03-26

Family

ID=59624790

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3013942A Active CA3013942C (en) 2016-02-17 2017-02-17 Compositions and methods for the treatment of sinus disease and disorders

Country Status (14)

Country Link
US (1) US11357791B2 (OSRAM)
EP (1) EP3416655A4 (OSRAM)
JP (1) JP2019505538A (OSRAM)
KR (1) KR20180108811A (OSRAM)
CN (1) CN108697731A (OSRAM)
AU (1) AU2017220396B2 (OSRAM)
BR (1) BR112018016651A2 (OSRAM)
CA (1) CA3013942C (OSRAM)
HK (1) HK1258884A1 (OSRAM)
IL (1) IL261134B2 (OSRAM)
MY (1) MY200434A (OSRAM)
SG (1) SG11201806835SA (OSRAM)
WO (1) WO2017139854A1 (OSRAM)
ZA (1) ZA201806103B (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11357791B2 (en) 2016-02-17 2022-06-14 Ent Technologies Pty Ltd Compositions and methods for the treatment of sinus disease and disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3563194B2 (ja) * 1996-03-15 2004-09-08 株式会社ノエビア 塩化ナトリウム含有ゲル組成物及びその製造方法
JPH11189533A (ja) * 1997-12-25 1999-07-13 Taisho Pharmaceut Co Ltd 点眼薬
US6214376B1 (en) * 1998-08-25 2001-04-10 Banner Pharmacaps, Inc. Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
US6518244B2 (en) * 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
JP2002302448A (ja) * 2001-04-02 2002-10-18 Shiseido Co Ltd 皮膚外用剤
CN1491724A (zh) * 2003-09-02 2004-04-28 无锡杰西医药科技有限公司 一种适用于青光眼治疗的成胶增稠用多糖系统
EP1930015A1 (en) 2006-12-05 2008-06-11 Marinomed Biotechnologie GmbH Use of carrageenan for treating rhinovirus infections
US20080317791A1 (en) 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Kappa Carrageenan
JP2011219412A (ja) * 2010-04-09 2011-11-04 Saisentan Igaku Kenkyusho:Kk 緑内障の視野改善治療薬
WO2012103575A1 (en) 2011-02-02 2012-08-09 Ent Technologies Pty Ltd Compositions and methods for the treatment of nasal passages
WO2012126777A1 (en) 2011-03-18 2012-09-27 Marinomed Biotechnologie Gmbh Inhibition of neuraminidase activity
RU2015136769A (ru) 2013-02-05 2017-03-13 Дзе Попьюлейшн Каунсил, Инк. Внутривагинальное кольцо для доставки уникальных комбинаций противомикробных композиций
CA2932237C (en) * 2013-12-03 2022-12-13 Gerolymatos International S.A. Ionic aqueous compositions comprising sulfated polysaccharides
EP3099292A1 (en) * 2014-01-28 2016-12-07 Resdevco Research and Development Co. Ltd. Composition comprising xylitol and cholecalciferol for topical treatment of skin and mucous membranes
DE102015110674A1 (de) 2015-07-02 2017-01-05 Sms Group Gmbh Umbausystem für einen Elektrolichtbogenofen (EAF)
CN107847430B (zh) * 2015-07-14 2021-02-02 玛丽诺姆德生物技术股份公司 一种具有抗病毒活性的鼻塞疏通组合物
US11357791B2 (en) 2016-02-17 2022-06-14 Ent Technologies Pty Ltd Compositions and methods for the treatment of sinus disease and disorders

Also Published As

Publication number Publication date
US20200276226A1 (en) 2020-09-03
IL261134A (en) 2018-10-31
IL261134B2 (en) 2023-03-01
US11357791B2 (en) 2022-06-14
MY200434A (en) 2023-12-26
EP3416655A4 (en) 2019-11-20
ZA201806103B (en) 2019-07-31
JP2019505538A (ja) 2019-02-28
EP3416655A1 (en) 2018-12-26
BR112018016651A2 (pt) 2018-12-26
KR20180108811A (ko) 2018-10-04
WO2017139854A1 (en) 2017-08-24
AU2017220396B2 (en) 2022-12-15
AU2017220396A1 (en) 2018-10-04
HK1258884A1 (zh) 2019-11-22
CN108697731A (zh) 2018-10-23
CA3013942A1 (en) 2017-08-24
SG11201806835SA (en) 2018-09-27
IL261134B (en) 2022-11-01

Similar Documents

Publication Publication Date Title
US9173901B2 (en) Compositions and methods of using lamellar bodies for modifying linear biological macromolecules
AU2014359488A1 (en) Ionic aqueous compositions
CA2724277A1 (en) Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
Casale et al. Hyaluronic acid and upper airway inflammation in pediatric population: a systematic review
Harvey et al. Local drug delivery
Sang et al. Sprayable berberine–silk fibroin microspheres with extracellular matrix anchoring function accelerate infected wound healing through antibacterial and anti-inflammatory effects
US20140186290A1 (en) Nanoparticle based therapy for dispersing mucin
AU2017220396B2 (en) Compositions and methods for the treatment of sinus disease and disorders
JP2022540702A (ja) 膀胱内注入用の医薬用及び/又は製薬用組成物、その製造及び用途
Macchi et al. Recurrent acute rhinosinusitis: a single blind clinical study of N-acetylcysteine vs ambroxol associated to corticosteroid therapy
CN111615384A (zh) 鼻窦炎的治疗方法
WO2022052454A1 (zh) 含酯基芳香丙酰胺类化合物在制备治疗干眼症药物中的应用
La Mantia et al. Efficacy, Safety, and Tolerability of Nasal Wash in Patients with Upper Respiratory Tract Diseases
US20170136101A1 (en) Methods for preventing and/or treating nasal polyps and rhinosinusitis
ITUB20156870A1 (it) Combinazione sinergica di acido pirrolidoncarbossilico e/o suoi sali o derivati e acido ialuronico e/o suoi sali, per uso nel trattamento e/o prevenzione della secchezza e dell'irritazione delle mucose, e relative formulazioni farmaceutiche.
CN105214071A (zh) 一种纤连蛋白类滴眼液及其制备方法
AU2012212385B2 (en) Compositions and methods for the treatment of nasal passages
CN102512664A (zh) 一种神经生长因子组合物
US10130639B1 (en) Homogeneous ophthalmic composition
Deng et al. Nebulized liposomal co-delivery of nintedanib and tetrandrine for enhanced treatment of pulmonary fibrosis
CA2540328C (en) Compositions and methods of using lamellar bodies for therapeutic purposes
CN101757638A (zh) 采用环糊精包合布地奈德的鼻用药物组合物
Sant'Ana et al. Effect of Budesonide Nasal Irrigation in Patients With Chronic Rhinosinusitis With Nasal Polyps Without Prior Sinus Surgery: A Randomized, Double‐Blind, Placebo‐Controlled Study
CN121243271A (zh) 一种通过抑制dht受体表达实现防脱生发的中药组合物及其制备方法
CN114129705A (zh) 一种多肽在预防和治疗肺炎的药物中的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220209

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - SMALL

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250204

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250204

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250204

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - SMALL

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251203